All Phil Johnson articles
-
NewsGilead’s Kite agrees $350m deal to acquire US biotech Interius BioTherapeutics
Will expand the company’s CAR T-cell therapy footprint and gain access next generation in vivo technology.
Will expand the company’s CAR T-cell therapy footprint and gain access next generation in vivo technology.